Side Effects: What Should I Expect?
General Considerations: Chemotherapy
Side effects from chemotherapy are different depending on the type of cancer you have and the combination of drugs given. Side effects may also be different from patient to patient and from treatment to treatment. This section discusses the most frequent and/or most serious side effects that patients experienced in the clinical trial studying ALIMTA plus cisplatin for NSCLC.
Side effects from chemotherapy should be monitored both by you and your healthcare team. Signs and symptoms such as fatigue, nausea, and vomiting are a few examples. Another group of side effects, such as those that change your blood cells, are monitored through regular blood tests, but they can also be identified through signs and symptoms you might experience.
Side effects can be serious if not treated. Though a few side effects can be permanent, many are temporary and go away after treatment dose is reduced or stopped.
ALIMTA in Combination with Cisplatin
ALIMTA is approved by the FDA in combination with cisplatin (another chemotherapy drug) for the initial treatment of advanced nonsquamous non-small cell lung cancer (NSCLC), a specific type of NSCLC. ALIMTA is not indicated for patients who have a different type of NSCLC called squamous cell.
Most patients taking ALIMTA will have side effects. This section will discuss some of the most common and/or most important side effects associated with ALIMTA plus cisplatin for the first-line treatment of advanced nonsquamous NSCLC. Sometimes it is not always possible to tell whether ALIMTA, cisplatin, or the cancer itself is causing these side effects, but you should always tell your healthcare team if you are experiencing anything new. Call your healthcare team right away if you have a fever, chills, diarrhea, or mouth sores. These symptoms could mean you have an infection.
Make sure that you follow your healthcare team's instructions regarding your ALIMTA pre-medications. This should help lessen the severity of the side effects you may experience.
For more information about all of the side effects noted in the clinical trial of ALIMTA plus cisplatin for NSCLC, please talk with your healthcare team, see the Patient Prescribing Information and full Prescribing Information, or call 1-800-545-5979.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Side effects you and your healthcare team should monitor
Additional side effects you'll want to monitor
Drug delays and discontinuation
When to call your healthcare team
Side effects you and your healthcare team should monitor
Before and during your treatment with ALIMTA plus cisplatin, you will have regular blood tests that will monitor you for the following side effects. You may also have symptoms that you must tell your healthcare team about.
Low white blood cell count (neutropenia/leukopenia)
White blood cells help you fight infection. In a clinical trial, about 29% of patients on ALIMTA plus cisplatin had a lowered white blood cell count.
You most likely will have a drop in your white blood cell count beginning several days after you receive ALIMTA plus cisplatin. During this time, you are more likely to develop an infection, and
you should avoid crowds and those with colds. You should call your healthcare team right away if you have any signs of infection, such as chills or a temperature over 100.4°F. There are medications to help with low white blood cell counts.
Low red blood cell count (anemia)
Red blood cells help transport oxygen from your lungs to the
other parts of your body. A low red blood cell count is called
anemia. If your red blood cell count is low, you may feel tired,
get tired easily, appear pale, and become short of breath. Anemia was experienced by 33% of patients receiving ALIMTA plus cisplatin in the clinical trial.
Low platelet count (thrombocytopenia)
Platelets help your blood to clot. A lowered platelet count puts you at more risk for bleeding. If your healthcare team tells you that
you have a low platelet count, you may be asked to take some precautions, including avoiding injury, using stool softeners, using soft-bristle toothbrushes, etc. It is important that you call your healthcare team if you see any signs of bleeding, such as bruising or blood in your stool. Among patients receiving ALIMTA plus cisplatin in the clinical trial, 10% had a low platelet count.
Additional side effects you'll want to monitor
-
Fever
Fever may be the first symptom of infection, but it may also be a result of the chemotherapy itself (without infection). There are medications that may reduce a fever that can be given along with chemotherapy. If you have a fever of 100.4°F or higher, you should call your healthcare team right away. - Tiredness (fatigue)
In the clinical trial, 43% of patients receiving ALIMTA plus cisplatin had some degree of fatigue. If you experience fatigue, some ideas to counteract it include balancing your periods of activity with rest; increasing your fluid intake; and following a well-balanced diet with several small meals, rather than 3 large meals. - Gastrointestinal upset
Be sure to talk with your healthcare team if you notice any of the following side effects or anything different about the way you feel. -
-
Nausea and/or vomiting
In the clinical trial, 56% of patients treated with ALIMTA plus cisplatin experienced some degree of nausea, and 40% experienced vomiting. It is important that you tell your healthcare team if you have nausea or vomiting. There are medications that can help prevent and treat nausea and vomiting. -
Loss of appetite (anorexia)
Loss of appetite occurred in 27% of patients receiving ALIMTA plus cisplatin. If you experience a loss of appetite, please be sure to tell your healthcare team. Also, the National Cancer Institute (NCI) has a helpful booklet titled Eating Hints, which you can obtain by calling 1-800-4CANCER (1-800-422-6237) or visiting the NCI Web site at www.cancer.gov. -
Constipation
Twenty-one percent of patients treated with ALIMTA plus cisplatin had constipation. Your healthcare team can help you treat your constipation. It is important that you talk with them before you take any over-the-counter laxatives or stool softeners. -
Diarrhea
Among patient receiving ALIMTA plus cisplatin, 12% experienced diarrhea. Tell your healthcare team if you have diarrhea. It is very important that you talk with them before you take any over-the-counter diarrhea medicines.
-
Nausea and/or vomiting
-
Mouth, lip, or throat sores (stomatitis/pharyngitis)
Fourteen percent of patients on ALIMTA plus cisplatin experienced redness or sores in their mouth, throat, or on their lips. These symptoms may happen a few days after ALIMTA plus cisplatin treatment. Talk with your healthcare team about proper mouth, lip, and throat care.
-
Hair loss (alopecia)
In the clinical trial, 12% of patients treated with ALIMTA plus cisplatin experienced some degree of alopecia, or hair loss. This was not permanent.
-
Nerve damage (neuropathy)
Among patients receiving ALIMTA plus cisplatin, 9% experienced some form of nerve damage. Symptoms of neuropathy may include weakness, pain, a tingling sensation, or numbness and tingling, especially in the toes and fingertips.
-
Rash
Among patients treated with ALIMTA plus cisplatin, 7% developed a rash. Talk to your healthcare team if you get a severe rash or itching. They will prescribe a medication (a steroid) to reduce the incidence and/or severity of this side effect.
Contact your healthcare team right away if you have fever, chills, diarrhea, or mouth sores. These symptoms could mean you have an infection.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
Talk with your healthcare team
As mentioned many times in this website, it is important for you to talk with your healthcare team about any questions or concerns you have as you move through your cancer experience.
Drug delays and discontinuation
You will have regular blood tests before and during your treatment with ALIMTA plus cisplatin. Your healthcare team may adjust your dose of ALIMTA or delay treatment based on the results of your blood tests or your general condition.
Side effects may or may not be caused by the drug treatment itself; some effects may be due to the disease or to other reasons. Contact your healthcare team right away if you have fever, chills, diarrhea, or mouth sores. These symptoms could mean you have an infection. Talk with your healthcare team if you have any side effects that bother you or don't go away.
When to call your healthcare team
You are probably attuned to changes in your body now more than ever. You must never take these changes for granted. As a person living with cancer, you must always be aware of infection. If you suspect an infection of any kind, call your healthcare team immediately.
According to the American Cancer Society, you should also alert your healthcare team right away if you notice any other changes in your body or experience any of the following symptoms during your chemotherapy treatment1:
- A fever of 100.5°F or greater
- Bleeding or unexplained bruising
- A rash or allergic reaction such as swelling or severe itching or wheezing
- Intense chills
- Pain or soreness at the chemotherapy injection site or catheter site
- Unusual pain including intense headaches
- Shortness of breath
- Prolonged diarrhea or vomiting
- Bloody stool or blood in your urine
Important Safety Information for ALIMTA (pemetrexed for injection)
ALIMTA is approved by the FDA in combination with cisplatin (another chemotherapy drug) for the initial treatment of advanced nonsquamous non-small cell lung cancer (NSCLC), a specific type of NSCLC. ALIMTA is not indicated for patients who have a different type of NSCLC called squamous cell.
ALIMTA as a single agent (used alone) is approved for maintaining the initial treatment effect of chemotherapy in patients with advanced nonsquamous non-small cell lung cancer whose disease has not worsened after initial therapy. ALIMTA is not indicated for patients who have another type of non-small cell lung cancer called squamous cell.
ALIMTA is approved by the FDA as a single agent (used alone) for the treatment of patients with advanced nonsquamous non-small cell lung cancer (NSCLC), a specific type of NSCLC, after prior chemotherapy. ALIMTA is not indicated for patients who have a different type of NSCLC called squamous cell.
ALIMTA is a treatment for malignant pleural mesothelioma (MPM), which is a cancer that affects the inside lining of the chest cavity. ALIMTA is given with cisplatin, another anticancer medicine (chemotherapy), when surgery is not an option.
ALIMTA may not be appropriate for some patients. If you are allergic to ALIMTA, tell your doctor because you should not receive it. If you think you are pregnant, are planning to become pregnant, or are nursing, please tell your healthcare team. ALIMTA may harm your unborn or nursing baby. Your physician may advise you to use effective contraception (birth control) to prevent pregnancy while you are being treated with ALIMTA.
If you have liver or kidney problems, be sure to tell your doctor. Your dose of ALIMTA may have to be changed, or ALIMTA may not be right for you. There is a risk of side effects associated with ALIMTA therapy. ALIMTA can suppress bone marrow function. It is very important to take folic acid and vitamin B12 prior to and during your treatment with ALIMTA to lower your chances of harmful side effects.
Your healthcare professional will prescribe a medicine called a corticosteroid, which lowers your chances of getting skin reactions with ALIMTA. Ask your healthcare professional before taking medicines called NSAIDs (nonsteroidal anti-inflammatory drugs used to treat pain or swelling). Tell your doctor if you are taking other medicines, including prescription and non-prescription medicines, vitamins, and herbal supplements.
The most common side effects of ALIMTA when given alone or in combination with cisplatin, another chemotherapy drug, are low blood cell counts (red blood cells, white blood cells, and platelets); tiredness; stomach upset, including nausea, vomiting, and diarrhea; mouth, throat, or lip sores; loss of appetite; rash; and constipation.
Call your healthcare professional right away if you have a fever, chills, diarrhea, or mouth sores. These symptoms could mean you have an infection. These are not all of the side effects of ALIMTA. If you have any side effect that bothers you or that doesn't go away, be sure to talk with your healthcare professional.
You will have regular blood tests before and during your treatment with ALIMTA. Your doctor may adjust your dose of ALIMTA or delay your treatment based on the results of your blood test and on your general condition.
For more information about all of the side effects of ALIMTA, please talk with your healthcare team, see the Patient Prescribing Information and full Prescribing Information, or call 1-800-545-5979.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
SG24
Reference:
- The American Cancer Society. When Do I Call My Doctor? Available at:
http://www.cancer.org/docroot/ETO/content/ETO_1_7X_When_Do_I_Call_My_Doctor.asp.
Accessed January 23, 2009.














